Nasdaq:US$15.42 (+0.02) | HKEX:HK$24.46 (+0.26) | AIM:£2.34 (+0.05)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2013-04-06

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors